Posts tagged ANTH
HCW starts Anthera Pharma at buy

H.C. Wainwright initiated coverage of Anthera Pharmaceuticals (NASDAQ:ANTH) with a “buy” rating and $10 price target. The stock closed at $3.38 on Thursday.

“We believe that at this time Anthera’s pipeline and value proposition has bifurcated into two components of very different risk/reward,” writes analyst Andrew Fein.

Read More